|
Leukemia, Myelocytic, Acute
|
0.600 |
Biomarker
|
disease |
BEFREE |
11q23 translocations (t(11q23)) are recurring cytogenetic abnormalities in both acute myeloid leukemia (AML) and acute lymphoblastic leukemia, involving the same gene, ALL1 (or MLL).
|
9529125 |
1998 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
Biomarker
|
disease |
BEFREE |
90.8% of MLL-PTD AML patients had at least one additional gene mutation.
|
26375248 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Acute myeloid leukemia (AML) patients with chromosome 11q23 abnormalities or MLL rearrangements have a poor prognosis when treated with conventional chemotherapy.
|
11999359 |
2002 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Acute myeloid leukaemia, French-American-British M4 and M5 subtypes (AML-M4/M5) is frequently associated with MLL gene rearrangement and its incidence is relatively high among infants.
|
19120366 |
2009 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
AML with chromosomal translocations involving the mixed lineage leukemia (MLL) gene are usually associated with poor survival.
|
23798388 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Acute myeloid leukemias with MLL rearrangements are frequently associated with myelomonocytic and monoblastic/monocytic morphology, with an increased risk of leukocytosis and leukostasis-related complications.
|
25081372 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
Biomarker
|
disease |
BEFREE |
Acute myeloid leukemias driven by MLL fusion proteins are commonly associated with poor prognosis and refractory treatment.
|
28886273 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Acute myeloid leukemia with hypergranular cytoplasm accompanied by t(X;11)(q24;q23) and rearrangement of the MLL gene.
|
9933140 |
1999 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MLL gene rearrangement in t(9;11) acute myelogenous leukemia with minimal myeloid differentiation (FAB subtype M0).
|
10846829 |
2000 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
Biomarker
|
disease |
BEFREE |
MLL rearrangements were not only detected in M5 (four of 12 patients, 33%) and M4 (six of 31, 19%) subtypes but also in other non-M4-M5 AML (six of 70, 9%), including M1, M2 and M7, but not M3 subtype.
|
10865968 |
2000 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
Biomarker
|
disease |
BEFREE |
MLL gene rearrangement in acute myelogenous leukemia after exposure to tegafur/uracil.
|
11939265 |
2002 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
Biomarker
|
disease |
BEFREE |
MLL abnormalities were more frequently found in AML-M5 and M4, mainly as rearrangements, and in AML-M2, mainly as overrepresentation.
|
16102580 |
2005 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
Biomarker
|
disease |
BEFREE |
MLL(+) was identified in 114 (98 adults) of 988 AML patients.
|
16341046 |
2006 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
Biomarker
|
disease |
BEFREE |
MLL fusion genes are a predominant feature of acute leukemias in infants and in secondary acute myeloid leukemia (AML) associated with prior chemotherapy with topo-II poisons.
|
16688745 |
2006 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
Biomarker
|
disease |
BEFREE |
MLL-SEPT6 fusion transcript with a novel sequence in an infant with acute myeloid leukemia.
|
16843108 |
2006 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
Biomarker
|
disease |
BEFREE |
MLL-AF9 is the most frequent MLL rearrangement in childhood acute myeloid leukemia (AML) and it may be also found in acute lymphoblastic leukemia (ALL) of patients younger than 1-year-old (infants).
|
18000862 |
2008 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MLL rearrangements in humans lead to both acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL).
|
18538728 |
2008 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
Biomarker
|
disease |
BEFREE |
MLL has been fused to ELL exon 2 in all the previously reported MLL-ELL transcripts, which have always been associated with AML.
|
18617060 |
2008 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MLL rearrangement with t(6;11)(q15;q23) as a sole abnormality in a patient with de novo acute myeloid leukemia: conventional cytogenetics, FISH, and multicolor FISH analyses for detection of rare MLL-related chromosome abnormalities.
|
18992643 |
2008 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
Biomarker
|
disease |
BEFREE |
MLL/AF4 and AML/MTG8 represent two leukemic fusion genes, which are most frequently found in infant acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), respectively.
|
20686504 |
2010 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MLL-PTD occurs predominantly in myeloid dysplasia syndromes, secondary AML (s-AML), and de novo AML.
|
23054645 |
2012 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
Biomarker
|
disease |
BEFREE |
MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation.
|
25387813 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MLL aberrations are detected in around 5-10% of acute myeloid and lymphatic leukemias and an additional 5% of acute myeloid leukemias show a partial internal MLL duplication (PTD).
|
25510485 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
Biomarker
|
disease |
BEFREE |
MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.
|
26927674 |
2016 |
|
Leukemia, Myelocytic, Acute
|
0.600 |
Biomarker
|
disease |
BEFREE |
KMT2A-MLLT10 is one of the common chimeric genes diagnosed in acute leukemia with KMT2A rearrangement (8%), especially in acute myeloid leukemia (AML; 18%).
|
30624859 |
2019 |